Reuben Benjamin

Consultant Haematologist and Clinical Senior Lecturer

King's College Hospital

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Reuben Benjamin is a Consultant Haematologist and Clinical Senior Lecturer at Kings College Hospital in the UK. His research focuses on CAR-T cell therapies and their applications in treating hematological malignancies, including multiple myeloma and large B-cell lymphoma. Recent publications highlight clinical outcomes and treatment strategies involving chimeric antigen receptor T-cell therapy and hematopoietic cell transplantation.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (12)

Christian Chabannon

Professor in Cell Biology

Aix-Marseille Université Faculté de Medecine

FRANCE

View details

Sally Barrington

King’s College London

UNITED KINGDOM

View details

Sapna shah

Honorary Senior Lecturer

King’s College London

UNITED KINGDOM

View details

Eitan Mirvis

Imperial College Healthcare NHS Trust

UNITED KINGDOM

View details

Philippe Moreau

FRANCE

View details

Holger Auner

Full Professor (Professeur ordinaire)

University of Lausanne

SWITZERLAND

View details

Hang Quach

University of Melbourne

AUSTRALIA

View details

Nizar J. Bahlis

University of Calgary

CANADA

View details

Andrea Kuhnl

King's College Hospital

UNITED KINGDOM

View details

Marion Subklewe

LMU University Hospital

GERMANY

View details

Aurore Perrot

Professor of Hematology

Université Paul Sabatier

FRANCE

View details

Niels W. C. J. van de Donk

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Reuben Benjamin

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients

CAR-T cells – the future for cancer therapy

MTV-guided radiotherapy bridging in large B-cell lymphoma patients receiving CD19 CAR T-cell therapy

Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Are we there yet? CAR‐T therapy in multiple myeloma

High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma

LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Comparison of autologous and allogeneic hematopoietic cell transplantation strategies in patients with primary plasma cell leukemia, with dynamic prediction modeling

Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study

Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option

LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma.

Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation.

Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma.

Efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in comparison with standard twice-weekly bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the BOSTON study.

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk.

Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma.

Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma.

Correction to: ICU-outcomes in CAR-T patients-A single centre experience.

Human Herpesvirus 6 Encephalitis Following <i>Axicabtagene Ciloleucel</i> Treatment for Refractory Diffuse Large B Cell Lymphoma.

Collaborators (12)

Christian Chabannon

Sally Barrington

Sapna shah

Eitan Mirvis

Philippe Moreau

Holger Auner

Hang Quach

Nizar J. Bahlis

Andrea Kuhnl

Marion Subklewe

Aurore Perrot

Niels W. C. J. van de Donk

Make your next move.